From the *Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany; †Department of Radiology, Faculty of Medicine, Cairo University, Cairo, Egypt; ‡Department of Surgery, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany; and §Department of Radiology, Alexandria Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Invest Radiol. 2014 Jan;49(1):48-56. doi: 10.1097/RLI.0b013e3182a6094e.
The purpose of this study was the evaluation of prognostic factors for long-term survival and progression-free survival (PFS) after treatment of colorectal cancer (CRC) liver metastases with magnetic resonance-guided laser-induced interstital thermotherapy (LITT).
We included 594 patients (mean age, 61.2 years) with CRC liver metastases who were treated with LITT. The statistical analysis of the long-term survival and PFS were based on the Kaplan-Meier method. The Cox regression model tested different parameters that could be of prognostic value. The tested prognostic factors were the following: sex, age, the location of primary tumor, the number of metastases, the maximal diameter and total volume of metastases and necroses, the quotient of total volumes of metastases and necroses, the time of appearance of liver metastases and location in the liver, the TNM classification of CRC, extrahepatic metastases, and neoadjuvant treatments.
The median survival was 25 months starting from the date of the first LITT. The 1-, 2-, 3-, 4-, and 5-year survival rates were 78%, 50.1%, 28%, 16.4%, and 7.8%, respectively. The median PFS was 13 months. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 51.3%, 35.4%, 30.7%, 25.4%, and 22.3%, respectively. The number of metastases and their maximal diameter were the most important prognostic factors for both long-term survival and PFS. Long-term survival was also highly influenced by the initial involvement of the lymph nodes.
For patients treated with LITT for CRC liver metastases, the number and size of metastases, together with the initial lymph node status, are significant prognostic factors for long-term survival.
本研究旨在评估磁共振引导激光间质热疗(LITT)治疗结直肠癌(CRC)肝转移患者的长期生存和无进展生存(PFS)的预后因素。
我们纳入了 594 例接受 LITT 治疗的 CRC 肝转移患者(平均年龄 61.2 岁)。采用 Kaplan-Meier 法对长期生存和 PFS 进行统计分析。Cox 回归模型测试了可能具有预后价值的不同参数。测试的预后因素包括:性别、年龄、原发肿瘤位置、转移灶数量、转移灶和坏死灶的最大直径和总体积、转移灶和坏死灶总体积比、肝转移出现时间和位置、CRC 的 TNM 分期、肝外转移以及新辅助治疗。
从首次 LITT 日期开始计算,中位生存期为 25 个月。1、2、3、4 和 5 年生存率分别为 78%、50.1%、28%、16.4%和 7.8%。中位 PFS 为 13 个月。1、2、3、4 和 5 年 PFS 率分别为 51.3%、35.4%、30.7%、25.4%和 22.3%。转移灶数量及其最大直径是长期生存和 PFS 的最重要预后因素。长期生存也受到淋巴结初始受累的高度影响。
对于接受 LITT 治疗的 CRC 肝转移患者,转移灶的数量和大小,以及初始淋巴结状态是长期生存的重要预后因素。